4.7 Article

Identification of Gene Mutations and Fusion Genes in Patients with Sezary Syndrome

期刊

JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 136, 期 7, 页码 1490-1499

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2016.03.024

关键词

-

资金

  1. Spanish Ministry of Economy and Competitiveness [SAF2013-49108-R]
  2. Red Tematica de Investigacion Cooperativa en Cancer, Fondo Europeo de Desarrollo Regional [RD12/0036/0044]
  3. Generalitat de Catalunya AGAUR [2014 SGR-1138, 2014 SGR-585]
  4. European Commission [282510, 262055, 625356]
  5. Instituto de Salud Carlos III FEDER [PT13/0010/0005]
  6. Pla Director d'Oncologia de Catalunya
  7. Spanish Ministry of Economy and Competitiveness, Centro de Excelencia Severo Ochoa [SEV-2012-0208]

向作者/读者索取更多资源

Sezary syndrome is a leukemic form of cutaneous T-cell lymphoma with an aggressive clinical course. The genetic etiology of the disease is poorly understood, with chromosomal abnormalities and mutations in some genes being involved in the disease. The goal of our study was to understand the genetic basis of the disease by looking for driver gene mutations and fusion genes in 15 erythrodermic patients with circulating Sezary cells, 14 of them fulfilling the diagnostic criteria of Sezary syndrome. We have discovered genes that could be involved in the pathogenesis of Sezary syndrome. Some of the genes that are affected by somatic point mutations include ITPR1, ITPR2, DSC1, RIPK2, IL6, and RAG2, with some of them mutated in more than one patient. We observed several somatic copy number variations shared between patients, including deletions and duplications of large segments of chromosome 17. Genes with potential function in the T-cell receptor signaling pathway and tumorigenesis were disrupted in Sezary syndrome patients, for example, CBLB, RASA2, BCL7C, RAMP3, TBRG4, and DAD1. Furthermore, we discovered several fusion events of interest involving RASA2, NFKB2, BCR, FASN, ZEB1, TYK2, and SGMS1. Our work has implications for the development of potential therapeutic approaches for this aggressive disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy

Julia Eckardt, Christopher Schroeder, Peter Martus, Sorin Armeanu-Ebinger, Olga Kelemen, Axel Gschwind, Irina Bonzheim, Thomas Eigentler, Teresa Amaral, Stephan Ossowski, Olaf Riess, Lukas Flatz, Claus Garbe, Andrea Forschner

Summary: BRAF mutation status and tumor mutational burden (TMB) were found to be independent predictive factors for relapse-free survival (RFS) in melanoma patients receiving adjuvant anti-PD-1 therapy. Patients with BRAF V600E/K mutation and high TMB had the best outcomes. A classification based on BRAF mutation status and TMB is proposed to predict RFS in these patients.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Article Genetics & Heredity

Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2

Laura Castilla-Vallmanya, Monica Centeno-Pla, Mercedes Serrano, Hector Franco-Valls, Raul Martinez-Cabrera, Aina Prat-Planas, Elena Rojano, Juan A. G. Ranea, Pedro Seoane, Clara Oliva, Abraham J. Paredes-Fuentes, Gemma Marfany, Rafael Artuch, Daniel Grinberg, Raquel Rabionet, Susanna Balcells, Roser Urreizti

Summary: Schaaf-Yang syndrome (SYS) is a genetic disorder caused by truncating mutations in the MAGEL2 gene. This study found that SYS patients have decreased levels of secreted A beta(1-40) peptide and identified several differentially expressed genes. The truncated form of MAGEL2 protein is stable and mainly localizes in the nucleus, suggesting it may exert a pathogenic effect. Understanding these findings may improve the management of SYS.

JOURNAL OF MEDICAL GENETICS (2023)

Article Hematology

NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition

Salvador Carrillo-Tornel, Tzu Hua Chen-Liang, Maria Zurdo, Anna Puiggros, Andrea Gomez-Llonin, Maria Dolores Garcia-Malo, Ernesto Jose Cuenca-Zamora, Francisco Jose Ortuno, Ana Maria Hurtado Lopez, Blanca Espinet, Andres Jerez

Summary: Prior studies have shown that chronic lymphocytic leukemia (CLL) has an indolent course due to dysregulated cyclin genes keeping most cells in the G(0)-G(1) cell cycle phase. This dysregulation is also observed in T lymphoblastic leukemia with NOTCH1 mutation. This study aimed to comprehensively investigate the cell cycle in NOTCH1-mutated CLL and identify potential therapeutic targets. The results revealed a distinct transcriptome profile in NOTCH1-mutated CLL cells, with an overexpression of early-phase effectors and increased cell cycling. Inhibition of NOTCH1 gamma-secretase and CDK4/6 showed promise as new therapeutic approaches for targeting NOTCH1-mutated CLL.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Oncology

Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches

Cristiana Roggia, Sorin Armeanu-Ebinger, Axel Gschwind, Olga Seibel-Kelemen, Sonja Hertler, Ulrike Faust, Alexandra Liebmann, Tobias B. Haack, Manuela Neumann, Irina Bonzheim, Andrea Forschner, Hans-Georg Kopp, Franziska Herster, Andreas Hartkopf, Michael Bitzer, Nisar P. Malek, Ines B. Brecht, Kristina Ruhm, Yvonne Moeller, Hubert Loewenheim, Stephan Ossowski, Olaf H. Riess, Christopher Schroeder

Summary: Sequencing of tumour tissue with gene panels is used for precision oncology. Tumour-normal pairs allow discrimination between somatic and germline alterations, which is important for patients and families.

EUROPEAN JOURNAL OF CANCER (2023)

Letter Hematology

Inactive T-cell prolymphocytic leukemia with negative surface CD3: Cytogenetic pitfalls

Marie Solange Flores-Moran, Juan Jose Rodriguez-Sevilla, Leonor Arenillas, Xavier Calvo, Ana Puiggros, Blanca Espinet, Beatriz Costan, Maria Rodriguez-Rivera, Marta Salido, Ana Ferrer del Alamo

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2023)

Article Oncology

Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse

Suzana Mittelstadt, Olga Kelemen, Jakob Admard, Axel Gschwind, Andre Koch, Sarah Woerz, Ernst Oberlechner, Tobias Engler, Irina Bonzheim, Annette Staebler, Nicola Weidner, Frank Stubenrauch, Thomas Iftner, Olaf Riess, Christopher Schroeder, Stefan Kommoss, Stephan Ossowski

Summary: This study found that cell-free circulating HPV-DNA in plasma can serve as a biomarker for therapy monitoring in cervical cancer. It is correlated with tumor burden and can be used to detect treatment response and relapse.

BRITISH JOURNAL OF CANCER (2023)

Article Clinical Neurology

First case of adult onset neuronal intranuclear inclusion disease with both typical radiological signs and NOTCH2NLC repeat expansions in a Caucasian individual

Iulian V. Podar, Daniel A. P. Gutmann, Florian Harmuth, Tobias B. Haack, Stephan Ossowski, Holger Hengel, Antje Bornemann, Ludger Schoels, Oliver Neuhaus

Summary: This case report describes a Caucasian female patient who presented with paroxysmal encephalopathy twice. Diagnosis was made using various methods including neurocranium magnetic resonance imaging, skin biopsy for histology, and long-read genome sequencing. The patient's MRI findings were consistent with typical features of adult onset neuronal intranuclear inclusion disease. Skin biopsy confirmed the presence of intranuclear inclusion bodies, and long-read genome sequencing revealed an expansion of the GGC repeat in exon 1 of NOTCH2NLC. This case highlights the possibility of adult onset NOTCH2NLC-GGC-positive NIID in non-Asian individuals.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Biochemistry & Molecular Biology

Do GWAS-Identified Risk Variants for Chronic Lymphocytic Leukemia Influence Overall Patient Survival and Disease Progression?

Antonio Jose Cabrera-Serrano, Jose Manuel Sanchez-Maldonado, Rob ter Horst, Angelica Macauda, Paloma Garcia-Martin, Yolanda Benavente, Stefano Landi, Alyssa Clay-Gilmour, Yasmeen Niazi, Blanca Espinet, Juan Jose Rodriguez-Sevilla, Eva Maria Perez, Rossana Maffei, Gonzalo Blanco, Matteo Giaccherini, James R. Cerhan, Roberto Marasca, Miguel Angel Lopez-Nevot, Tzu Chen-Liang, Hauke Thomsen, Irene Gamez, Daniele Campa, Victor Moreno, Silvia de Sanjose, Rafael Marcos-Gragera, Maria Garcia-Alvarez, Trinidad Dierssen-Sotos, Andres Jerez, Aleksandra Butrym, Aaron D. Norman, Mario Luppi, Susan L. Slager, Kari Hemminki, Yang Li, Sonja I. Berndt, Delphine Casabonne, Miguel Alcoceba, Anna Puiggros, Mihai G. Netea, Asta Foersti, Federico Canzian, Juan Sainz

Summary: Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults worldwide. However, a study found that the GWAS-identified risk variants for CLL do not significantly impact overall survival and disease progression in CLL patients. The polygenic risk scores (PRSs) built with these risk variants also have limited accuracy in predicting patient survival and disease progression.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Computer Science, Information Systems

Creation of a structured molecular genomics report for Germany as a local adaption of HL7's Genomic Reporting Implementation Guide

Caroline Stellmach, Julian Sass, Bernd Auber, Martin Boeker, Thomas Wienker, Andrew J. Heidel, Manuela Benary, Simon Schumacher, Stephan Ossowski, Frederick Klauschen, Yvonne Moeller, Rita Schmutzler, Arsenij Ustjanzew, Patrick Werner, Aurelie Tomczak, Thimo Hoelter, Sylvia Thun

Summary: The objective of this study was to develop a dataset definition, information model, and FHIR specification for key data elements in a German MolGen report. A core dataset of 76 data elements was created and a FHIR specification with 16 profiles was developed. This report can serve as a template for creating a standard format for unstructured genomic report data.

JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2023)

Article Genetics & Heredity

Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors

Luis Zapata, Giulio Caravagna, Marc J. Williams, Eszter Lakatos, Khalid AbdulJabbar, Benjamin Werner, Diego Chowell, Chela James, Lucie Gourmet, Salvatore Milite, Ahmet Acar, Nadeem Riaz, Timothy A. A. Chan, Trevor A. Graham, Andrea Sottoriva

Summary: In cancer, clones that can evade the immune system are selected by evolutionary forces. By analyzing thousands of primary tumors and immune-checkpoint-treated metastases, researchers have measured immune selection using immune dN/dS, which is the ratio of nonsynonymous to synonymous mutations in the immunopeptidome. This analysis helps differentiate between immune-edited and immune-escaped tumors and predicts the response to immunotherapies.

NATURE GENETICS (2023)

Article Immunology

Whole genome analysis of two sympatric human Mansonella: Mansonella perstans and Mansonella sp DEUX

Miriam Rodi, Caspar Gross, Thaisa Lucas Sandri, Lilith Berner, Marina Marcet-Houben, Ersoy Kocak, Michaela Pogoda, Nicolas Casadei, Carsten Koehler, Andrea Kreidenweiss, Selidji Todagbe Agnandji, Toni Gabaldon, Stephan Ossowski, Jana Held

Summary: This study investigated the relationship between Mansonella perstans and a potential new species called Mansonella sp DEUX in Gabon. By screening individuals in the area and generating whole genome data, it was found that Mansonella sp DEUX is a new Mansonella species. The availability of whole genome data will facilitate further research on these species.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2023)

Article Genetics & Heredity

Genome sequencing identifies complex structural MLH1 variant in unsolved Lynch syndrome

Dennis Witt, Ulrike Faust, Gertrud Strobl-Wildemann, Marc Sturm, Rebecca Buchert, Theresia Zuleger, Jakob Admard, Nicolas Casadei, Stephan Ossowski, Tobias B. Haack, Olaf Riess, Christopher Schroeder

Summary: This study used clinical genome sequencing and transcriptome sequencing to successfully detect a genetic variant in a patient with Lynch syndrome that could not be found using standard diagnostic tests. It also identified an previously undetected structural variant and identified additional high-risk family members through segregation analysis. The study highlights the advantages of clinical genome sequencing in detecting structural variants.

MOLECULAR GENETICS & GENOMIC MEDICINE (2023)

Editorial Material Dermatology

Relapsing annular lesions: a diagnostic challenge

Mariia Rivera, Emilio Lopez-Trujillo, Andrea Ciuda, Gemma Martin-Ezquerra, Ramon M. Pujol

Summary: We present a case of a 60-year-old patient who had several flares of nonscaling, erythematous, urticarial annular skin lesions on her abdomen, buttocks and proximal extremities, possibly related to COVID-19 vaccination. The skin biopsy revealed a dense infiltration of lymphocytes and abundant eosinophils, suggesting an inflammatory response.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2023)

Article Oncology

Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system

Mirjam Renovanz, Sylvia C. Kurz, Johannes Rieger, Bianca Walter, Hannes Becker, Hanni Hille, Paula Bombach, David Rieger, Lucia Grosse, Lara Haeusser, Marco Skardelly, Daniel J. Merk, Frank Paulsen, Elgin Hoffmann, Cihan Gani, Manuela Neumann, Rudi Beschorner, Olaf Riess, Cristiana Roggia, Christopher Schroeder, Stephan Ossowski, Sorin Armeanu-Ebinger, Axel Gschwind, Saskia Biskup, Martin Schulze, Falko Fend, Stephan Singer, Lars Zender, Claudia Lengerke, Sara Yvonne Brucker, Tobias Engler, Andrea Forschner, Arnulf Stenzl, Oliver Kohlbacher, Sven Nahnsen, Gisela Gabernet, Sven Fillinger, Benjamin Bender, Ulrike Ernemann, Oeznur Oener, Janina Beha, Holly Sundberg Malek, Yvonne Moeller, Kristina Ruhm, Marcos Tatagiba, Jens Schittenhelm, Michael Bitzer, Nisar Malek, Daniel Zips, Ghazaleh Tabatabai

Summary: This study investigates the feasibility and clinical utility of molecular profiling and targeted therapy in patients with advanced tumors in the nervous system. The results show that 93.1% of patients can receive biomarker-guided therapy recommendations, with treatment initiated in 22.6% of cases and a progression-free survival ratio >1.3 observed in 31.3% of patients. These findings support the clinical efficacy of biomarker-guided therapies in neuro-oncology patients and have implications for future clinical trials and care.

NEURO-ONCOLOGY ADVANCES (2023)

暂无数据